For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Progression free survival in Tafinlar® (dabrafenib) + Mekinist® (trametinib) patients

In 2 phase 3 studies, 22% to 24% of the patients who received first-line Tafinlar + Mekinist remained progression free at 3 years1,2

COMBI-v: 24% of the patients who received first-line Tafinlar + Mekinist remained progression free at 3 years1

Tafinlar® (dabrafenib) + Mekinist® (trametinib) progression free survival

 

  • In COMBI-v, the median PFS in patients who received Tafinlar + Mekinist was 12.1 months, and the median PFS with vemurafenib monotherapy was 7.3 months1

COMBI-d: 22% of the patients who received first-line Tafinlar + Mekinist remained progression free at 3 years2

Monotherapy progression free survival probability Tafinlar® (dabrafenib) + Mekinist® (trametinib)

 

  • In COMBI-d, the median PFS in patients who received Tafinlar + Mekinist was 11.0 months and the median PFS with Tafinlar monotherapy was 8.8 months3

HR, hazard ratio; PFS, progression-free survival.

References: 1. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Presented at: European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. 2. Flaherty KT, Davies MA, Grob J, et al. Genomic analysis and 3-year efficacy and safety update of COMBI-d. J Clin Oncol. 2016;34(suppl) [abstract 9502]. 3. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.